GSK Consumer Split Set For July, With Emerging Markets And Switch To Drive Growth

GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.

Launch Plans words stamped in red ink on yellow envelope offering advice, information
• Source: Shutterstock

Rx-to-OTC switch, meeting demand for more natural OTC products and expanding in emerging markets will help GlaxoSmithKline’s standalone consumer health business grow faster than the market when it launches later this year, according to CEO designate Brian McNamara.

Speaking at GSK’s capital markets day, McNamara said the standalone business – which will be called Haleon – was expected to deliver organic annual sales growth of 4-6% over the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

‘We Must Have The Truth’ – Calls For UWWTD Review Intensify As Evidence Looks ‘Shaky’

 
• By 

The evidence underpinning the “polluter pays” principle of the revised Urban Wastewater Treatment Directive - which calls on Europe's pharmaceutical industry to cough up at least 80% of the cost of updating wastewater treatment facilities - is looking increasingly shaky, according to a new report.

Self-Care Must Be Central To NHS Reform, Says UK Industry And Pharmacy Alliance

 
• By 

Ahead of a soon to be released 10-Year Health Plan for the English NHS, an alliance including PAGB calls for self-care to be “clearly recognised and supported through concrete policies that reflect its vital role in achieving the plan’s goals.”

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

EU Parliament Calls For Review Of Wastewater Directive’s Impact On Pharma Sector

 
• By 

At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.

More from Geography

EU Parliament Calls For Review Of Wastewater Directive’s Impact On Pharma Sector

 
• By 

At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.

New Zealand Could Become First Country To Offer Gout Drug Allopurinol OTC

 
• By 

At the second attempt, New Zealand’s Medicines Classification Committee supported the Rx-to-OTC switch of allopurinol (100mg and 300mg) for people suffering from gout by specifically trained pharmacists.

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By 

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”